Delivery Order SPE2DB24D3015-SPE2DB25FFZYV
Award Date 6/30/25
Potential Completion Date 7/1/25
Potential Value $23K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $6,945.34 to AmerisourceBergen Drug Corp for REXULTI 2 mg tablets (30-count packages) on September 2, 2025, with completion scheduled for September 3, 2025. This non-set-aside, firm fixed-price contract represents a routine pharmaceutical procurement supporting federal medical supply chain operations. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- The U.S. Defense Logistics Agency (DLA) awarded a $6,495.49 firm-fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of 1 mg REXULTI tablets. This order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 that AmerisourceBergen holds with DLA Troop Support Medical to provide a comprehensive range of pharmaceutical and medical supplies in support of military healthcare programs. The contract does not have a set-aside designation and is expected to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,620.81 to AmerisourceBergen Drug Corp for the supply of REXULTI 2 mg tablets (30-count packaging) with a firm fixed price and an ultimate completion date of September 11, 2025. This non-set-aside competitive award was issued on September 10, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $19,710.72 to AmerisourceBergen Drug Corp for the supply of REXULTI 0.5 mg tablets in a 30-count package. The contract was competitively awarded without set-aside designation on May 27, 2025, with a completion date of May 28, 2025. This delivery order operates under a firm fixed-price arrangement and represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the provision of 4,563,969,451 REXULTI 0.5 mg tablets in quantities of 30. The $3,448.07 award has an ultimate completion date of March 15, 2024. This delivery order is part of a larger $999,999,999.00 indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, which serves as the primary vehicle for...
- The U.S. Defense Logistics Agency (DLA) awarded a $12,307.88 firm fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of REXULTI 2 MG TABLET 30S. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally....
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,259.26 for REXULTI 0.5 mg tablets (30-count packages) on August 12, 2025, with an ultimate completion date of August 13, 2025. This firm fixed-price, competitively awarded contract (no set-aside designation) leverages AmerisourceBergen's position as a prime vendor under the DLA Troop Support Medical Indefinite Delivery Contract SPE2DX, valued at $999,999,999.00 through December 2026. The pharmaceutical...
- The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide REXULTI 1 MG TABLET 30S, a pharmaceutical product. The $1,834.90 contract has a completion date of February 29, 2024 and does not have a set-aside designation. Amerisourcebergen Drug Corp, operating out of its Corporate Office in Conshohocken, Pennsylvania, is the prime contractor on this order, which is part of a...
- The Defense Logistics Agency awarded a delivery order valued at $3,448.30 to AmerisourceBergen Drug Corp for supply of REXULTI 0.5 mg tablets (30-count packages). This firm fixed-price, competitively awarded delivery order was issued on August 28, 2025, with an ultimate completion date of August 29, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corporation, a subsidiary of Amerisourcebergen Corporation, a firm fixed price delivery order contract valued at $6,296.68 for the supply of REXULTI 0.5 MG TABLET 30S. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract...